Novo's Ziltivekimab Fails Phase 3 Heart Trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Ziltivekimab missed its primary goal in a Phase 3 trial, failing to reduce cardiovascular death, heart attack, or stroke among more than 6,300 patients with heart disease, kidney disease, and inflammation
- The drug did lower markers of inflammation in trial participants, but that reduction did not translate into fewer major cardiovascular complications
- The result raises questions about the increasingly popular therapeutic approach of targeting inflammation to prevent cardiovascular complications
- Novo Nordisk shares fell about 7% on Friday following the announcement of the trial outcome
Why it matters: The failure undermines the inflammation-targeting hypothesis in cardiovascular medicine, an approach that had attracted significant industry investment. Novo Nordisk loses a pipeline candidate and saw shares drop roughly 7%, while the broader inflammation theory in cardiology now faces a high-profile setback that may temper further drug development in the space.
